Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 8 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

13%

1 trials in Phase 3/4

Results Transparency

0%

0 of 2 completed trials have results

Key Signals

4 recruiting

Enrollment Performance

Analytics

N/A
2(66.7%)
Phase 4
1(33.3%)
3Total
N/A(2)
Phase 4(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (8)

Showing 8 of 8 trials
NCT07056621Recruiting

Does Belimumab Modify the Natural History of SLE? A Propensity Score-matched, Real-world Study

Role: lead

NCT06501469Recruiting

Biomarkers in Parkinsonian Syndromes

Role: collaborator

NCT04570306Completed

Transcriptional and Immune Parameters of Response to Belimumab

Role: lead

NCT06208501Recruiting

The Predictive Role of Proteomics in Blood Pressure Response of Hypertensive Patients Undergoing Renal Denervation.

Role: collaborator

NCT05404295Phase 4Completed

The Effect of Treatment With Umbilical Cord Blood Platelet Lysate on Diabetic Foot Ulcers

Role: collaborator

NCT06083337Not ApplicableUnknown

Vascular Inflammation ReDuction and Perivascular Fat Imaging by Computed Tomography

Role: collaborator

NCT03308916Not ApplicableRecruiting

Screening At-risk Populations for Hepatic Fibrosis With Non-invasive Markers

Role: collaborator

NCT04167332Not Yet Recruiting

Prospective Collection of Samples for Urothelial Cancer of Bladder

Role: collaborator

All 8 trials loaded